R & d of an investigational new drug (IND) sponsor, compliant clinical trials leading to a new indication for valproic acid (VPA) for treatment of patients with significant hemorrhage, naval medical…
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH20C0122
- Awardee
-
Westat, Inc. UEI NVUWAFWQ57S5
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $3,742,408
Award facts
- Opportunity
-
- Valproic Acid for the Treatment of Significant Hemorrhage Pre-Solicitation · W81XWH20R0070 · Posted May 12, 2020
- Valproic Acid for the Treatment of Significant Hemorrhage Award Notice · Posted Oct 6, 2020
- Valproic Acid for the Treatment of Significant Hemorrhage Limited / Sole Source Justification · Posted Oct 6, 2020
- Contract value 100% obligated
- $3,742,407.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Bureau of Medicine and Surgery Department of the Navy, Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$107,593 | |
| Supplemental Agreement for work within scope | -$4,200,000 | |
| Terminate for Convenience | $0 | |
| Funding Only Action | $3,000,000 | |
| Funding Only Action | $1,500,000 | |
| Funding Only Action | $155,884 | |
| Funding Only Action | -$155,884 | |
| Original award | $3,550,000 |
About this award
Westat, Inc. was awarded a definitive cost-plus-fixed-fee contract valued at $3.7 million by the Department of the Navy Bureau of Medicine and Surgery to serve as the regulatory sponsor for the development of valproic acid as a treatment for significant hemorrhage. Under the terms of the contract, Westat will manage placebo-controlled randomized clinical trials of valproic acid in patients at high risk of hemorrhage and be responsible for all regulatory requirements until filing a New Drug Application with the U.S. Food and Drug Administration. The contract aims to support the Department of Defense and U.S. Army Medical Research and Development Command programs for Combat Casualty Care research by investigating an investigational new drug for the treatment of significant hemorrhage, a key focus area. Performance will take place in Potomac, Maryland over a three-year period concluding in December 2023.
Description
R & d of an investigational new drug (IND) sponsor, compliant clinical trials leading to a new indication for valproic acid (VPA) for treatment of patients with significant hemorrhage, naval medical research center
Quick answers
Who was awarded contract W81XWH20C0122?
W81XWH20C0122 was awarded to Westat, Inc. by Medical Command (Department of the Army) on September 25, 2020.
How much is contract W81XWH20C0122 worth?
The government has obligated $3,742,408 on W81XWH20C0122.
Which agency awarded contract W81XWH20C0122?
Medical Command (Department of the Army) awarded W81XWH20C0122, with funding from Bureau of Medicine and Surgery (Department of the Navy).
Was contract W81XWH20C0122 competed?
The extent of competition for W81XWH20C0122 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award